Pharvaris (PHVS) Change in Account Payables (2020 - 2026)
Pharvaris' (PHVS) quarterly Change in Account Payables came in at -$5.5 million in Q1 2026, down 1462.15% YoY from $406477.4 in Q1 2025, and down 221.57% on a QoQ basis from $4.6 million in Q4 2025.
Analysis
Pharvaris (PHVS) Change in Account Payables (2020 - 2026) Analysis & Trends
Pharvaris (PHVS) has 7 years of Change in Account Payables data on file, last reported at -$5.5 million in Q1 2026.
- Quarterly Change in Account Payables fell 1462.15% year-over-year to -$5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.2 million (down 272.0% YoY) and the FY2025 annual result came in at -$29272.3, down 101.64% from the prior year.
- Change in Account Payables eased to -$5.5 million in Q1 2026, from $4.6 million in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $1657.9 billion in Q3 2023 to a low of -$1658.4 billion in Q2 2023.
- A 5-year average of -$30.2 million and a median of $859138.2 in 2025 frame the typical range for Change in Account Payables.
- The widest YoY moves for Change in Account Payables: up 56176968.41% in 2023, down 188589424.78% in 2023.
- Tracing PHVS's Change in Account Payables over 5 years: stood at -$713969.1 in 2022, then slumped by 189.52% to -$2.1 million in 2023, then jumped by 119.05% to $393783.8 in 2024, then jumped by 1056.55% to $4.6 million in 2025, then slumped by 221.57% to -$5.5 million in 2026.
- The last three Change in Account Payables figures came in at -$5.5 million (Q1 2026), $4.6 million (Q4 2025), and -$5.1 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -8.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 5.03 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 37.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Pharvaris | 2.10 Bn | 1.73 Bn | 85,072.10 | -1.28 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.28 Mn |
| Mar 31, 2026 | -5.54 Mn |
| Dec 31, 2025 | 4.55 Mn |
| Sep 30, 2025 | -5.10 Mn |
| Jun 30, 2025 | 859,138.16 |
| Mar 31, 2025 | -354,436.67 |
| Dec 31, 2024 | 393,783.82 |
| Sep 30, 2024 | -64.49 Bn |
| Jun 30, 2024 | 63.23 Bn |
| Mar 31, 2024 | 2.88 Mn |
| Dec 31, 2023 | -2.07 Mn |
| Sep 30, 2023 | 1,657.85 Bn |
| Jun 30, 2023 | -1,658.37 Bn |
| Mar 31, 2023 | 1.30 Mn |
| Dec 31, 2022 | -713,969.11 |
| Sep 30, 2022 | -1,692.27 Bn |
| Jun 30, 2022 | 1,790.93 Bn |
| Mar 31, 2022 | 958,803.01 |
| Dec 31, 2021 | -1.21 Mn |
| Sep 30, 2021 | 419,751.99 |